Compare · CLOV vs ILMN
CLOV vs ILMN
Side-by-side comparison of Clover Health Investments Corp. (CLOV) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLOV and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $33.97B, about 15.5x CLOV ($2.19B).
- ILMN has been more active in the news (11 items in the past 4 weeks vs 8 for CLOV).
- ILMN has more recent analyst coverage (25 ratings vs 12 for CLOV).
- Company
- Clover Health Investments Corp.
- Illumina Inc.
- Price
- $4.13+0.73%
- $225.01+0.76%
- Market cap
- $2.19B
- $33.97B
- 1M return
- -3.50%
- -
- 1Y return
- +54.97%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 8
- 11
- Recent ratings
- 12
- 25
Clover Health Investments Corp.
Clover Health Investments, Corp. operates as a Medicare Advantage insurer in the United States. The company through its software platform provides preferred provider organization and health maintenance organization health plans for Medicare-eligible consumers. Clover Health Investments, Corp. was founded in 2014 and is headquartered in Franklin, Tennessee.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest CLOV
- Clover Health Investments Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Interim CFO Thornton Joseph Clay sold $78,032 worth of shares (17,775 units at $4.39), decreasing direct ownership by 1% to 1,249,526 units (SEC Form 4) (tax liability)
- Chief Legal Officer Soares Karen was granted 108,695 shares, increasing direct ownership by 7% to 1,614,217 units (SEC Form 4)
- Interim CFO Thornton Joseph Clay was granted 54,347 shares, increasing direct ownership by 4% to 1,267,301 units (SEC Form 4)
- Chief Executive Officer Toy Andrew sold $408,261 worth of shares (87,798 units at $4.65), decreasing direct ownership by 0.92% to 9,459,316 units (SEC Form 4) to satisfy withholding tax
- SEC Form 10-Q filed by Clover Health Investments Corp.
- Clover Health Investments Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Clover Health Reports Second Quarter 2026 Results
- Clover Health to Participate in Upcoming Canaccord Genuity 46th Annual Growth Conference
- Chief Legal Officer Soares Karen sold $233,167 worth of shares (51,700 units at $4.51) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 1,505,522 units (SEC Form 4)
Latest ILMN
- Director Meister Keith A. sold $145,556,398 worth of shares (679,574 units at $214.19) (SEC Form 4)
- SVP, Strategy/Corp Development Wedel Christensen Jakob sold $197,840 worth of shares (1,033 units at $191.52), decreasing direct ownership by 7% to 14,023 units (SEC Form 4)
- SEC Form 8-K filed by Illumina Inc.
- Illumina Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- SEC Form 8-K filed by Illumina Inc.
- SEC Form 3 filed by new insider Coletti Julie Ann
- SEC Form FWP filed by Illumina Inc.
- Chief Commercial Officer Sullivan Michael C was granted 4,503 shares (SEC Form 4)
- Illumina Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Director Meister Keith A. sold $148,159,897 worth of shares (741,127 units at $199.91) (SEC Form 4)